Cargando…

Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial

PURPOSE: Care bundles are recommended in patients at high risk for acute kidney injury (AKI), although they have not been proven to improve outcomes. We sought to establish the efficacy of an implementation of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines to prevent cardiac surgery...

Descripción completa

Detalles Bibliográficos
Autores principales: Meersch, Melanie, Schmidt, Christoph, Hoffmeier, Andreas, Van Aken, Hugo, Wempe, Carola, Gerss, Joachim, Zarbock, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633630/
https://www.ncbi.nlm.nih.gov/pubmed/28110412
http://dx.doi.org/10.1007/s00134-016-4670-3
_version_ 1783269924255301632
author Meersch, Melanie
Schmidt, Christoph
Hoffmeier, Andreas
Van Aken, Hugo
Wempe, Carola
Gerss, Joachim
Zarbock, Alexander
author_facet Meersch, Melanie
Schmidt, Christoph
Hoffmeier, Andreas
Van Aken, Hugo
Wempe, Carola
Gerss, Joachim
Zarbock, Alexander
author_sort Meersch, Melanie
collection PubMed
description PURPOSE: Care bundles are recommended in patients at high risk for acute kidney injury (AKI), although they have not been proven to improve outcomes. We sought to establish the efficacy of an implementation of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines to prevent cardiac surgery-associated AKI in high risk patients defined by renal biomarkers. METHODS: In this single-center trial, we examined the effect of a “KDIGO bundle” consisting of optimization of volume status and hemodynamics, avoidance of nephrotoxic drugs, and preventing hyperglycemia in high risk patients defined as urinary [TIMP-2]·[IGFBP7] > 0.3 undergoing cardiac surgery. The primary endpoint was the rate of AKI defined by KDIGO criteria within the first 72 h after surgery. Secondary endpoints included AKI severity, need for dialysis, length of stay, and major adverse kidney events (MAKE) at days 30, 60, and 90. RESULTS: AKI was significantly reduced with the intervention compared to controls [55.1 vs. 71.7%; ARR 16.6% (95 CI 5.5–27.9%); p = 0.004]. The implementation of the bundle resulted in significantly improved hemodynamic parameters at different time points (p < 0.05), less hyperglycemia (p < 0.001) and use of ACEi/ARBs (p < 0.001) compared to controls. Rates of moderate to severe AKI were also significantly reduced by the intervention compared to controls. There were no significant effects on other secondary outcomes. CONCLUSION: An implementation of the KDIGO guidelines compared with standard care reduced the frequency and severity of AKI after cardiac surgery in high risk patients. Adequately powered multicenter trials are warranted to examine mortality and long-term renal outcomes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00134-016-4670-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5633630
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-56336302017-10-23 Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial Meersch, Melanie Schmidt, Christoph Hoffmeier, Andreas Van Aken, Hugo Wempe, Carola Gerss, Joachim Zarbock, Alexander Intensive Care Med Seven-Day Profile Publication PURPOSE: Care bundles are recommended in patients at high risk for acute kidney injury (AKI), although they have not been proven to improve outcomes. We sought to establish the efficacy of an implementation of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines to prevent cardiac surgery-associated AKI in high risk patients defined by renal biomarkers. METHODS: In this single-center trial, we examined the effect of a “KDIGO bundle” consisting of optimization of volume status and hemodynamics, avoidance of nephrotoxic drugs, and preventing hyperglycemia in high risk patients defined as urinary [TIMP-2]·[IGFBP7] > 0.3 undergoing cardiac surgery. The primary endpoint was the rate of AKI defined by KDIGO criteria within the first 72 h after surgery. Secondary endpoints included AKI severity, need for dialysis, length of stay, and major adverse kidney events (MAKE) at days 30, 60, and 90. RESULTS: AKI was significantly reduced with the intervention compared to controls [55.1 vs. 71.7%; ARR 16.6% (95 CI 5.5–27.9%); p = 0.004]. The implementation of the bundle resulted in significantly improved hemodynamic parameters at different time points (p < 0.05), less hyperglycemia (p < 0.001) and use of ACEi/ARBs (p < 0.001) compared to controls. Rates of moderate to severe AKI were also significantly reduced by the intervention compared to controls. There were no significant effects on other secondary outcomes. CONCLUSION: An implementation of the KDIGO guidelines compared with standard care reduced the frequency and severity of AKI after cardiac surgery in high risk patients. Adequately powered multicenter trials are warranted to examine mortality and long-term renal outcomes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00134-016-4670-3) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2017-01-21 2017 /pmc/articles/PMC5633630/ /pubmed/28110412 http://dx.doi.org/10.1007/s00134-016-4670-3 Text en © The Author(s) 2017 Open AccessThe article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, a link is provided to the Creative Commons license and any changes made are indicated.
spellingShingle Seven-Day Profile Publication
Meersch, Melanie
Schmidt, Christoph
Hoffmeier, Andreas
Van Aken, Hugo
Wempe, Carola
Gerss, Joachim
Zarbock, Alexander
Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial
title Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial
title_full Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial
title_fullStr Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial
title_full_unstemmed Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial
title_short Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial
title_sort prevention of cardiac surgery-associated aki by implementing the kdigo guidelines in high risk patients identified by biomarkers: the prevaki randomized controlled trial
topic Seven-Day Profile Publication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633630/
https://www.ncbi.nlm.nih.gov/pubmed/28110412
http://dx.doi.org/10.1007/s00134-016-4670-3
work_keys_str_mv AT meerschmelanie preventionofcardiacsurgeryassociatedakibyimplementingthekdigoguidelinesinhighriskpatientsidentifiedbybiomarkerstheprevakirandomizedcontrolledtrial
AT schmidtchristoph preventionofcardiacsurgeryassociatedakibyimplementingthekdigoguidelinesinhighriskpatientsidentifiedbybiomarkerstheprevakirandomizedcontrolledtrial
AT hoffmeierandreas preventionofcardiacsurgeryassociatedakibyimplementingthekdigoguidelinesinhighriskpatientsidentifiedbybiomarkerstheprevakirandomizedcontrolledtrial
AT vanakenhugo preventionofcardiacsurgeryassociatedakibyimplementingthekdigoguidelinesinhighriskpatientsidentifiedbybiomarkerstheprevakirandomizedcontrolledtrial
AT wempecarola preventionofcardiacsurgeryassociatedakibyimplementingthekdigoguidelinesinhighriskpatientsidentifiedbybiomarkerstheprevakirandomizedcontrolledtrial
AT gerssjoachim preventionofcardiacsurgeryassociatedakibyimplementingthekdigoguidelinesinhighriskpatientsidentifiedbybiomarkerstheprevakirandomizedcontrolledtrial
AT zarbockalexander preventionofcardiacsurgeryassociatedakibyimplementingthekdigoguidelinesinhighriskpatientsidentifiedbybiomarkerstheprevakirandomizedcontrolledtrial